CAMP4 Therapeutics Stock

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

Sign up today and learn more about CAMP4 Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About CAMP4 Therapeutics Stock

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

Funding History

May 2018$30.0M
January 2020$15.0M
June 2021$45.0M
July 2022$100M

Management

CEO

Josh Mandel-Brehm

Founder

Leonard Zon

Founder

Richard Young

Associate Director & Head of Biology

Alla Sigova

VP, Portfolio Strategy & Business Operations

Caleb Moore

Board Member

Shaan Gandhi

Head of People

Tali Ronen

CSO

David Bumcrot

Board of Directors

James Boylan

Head of Discovery

Alfica Sehgal

CFO

Kelly Gold

Board Member

Amir Nashat

Board Member

Andrew Schwab

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo